|
| |
Lorus TherapeuticsLorus Therapeutics Inc. is a pharmaceutical company focused on the development of cancer therapies. Lorus' goal is to capitalize on its pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer.
The Company is currently developing a number of novel anti-cancer compounds called NuChem Analogues, based on a commonly used anti-fungal agent, clotrimazole. This technology includes the anti-cancer applications of clotrimazole itself. Clotrimazole has been shown to have unique anti-proliferative activities against cancer cells, including the inhibition of key steps in tumour growth and angiogenesis (new blood vessel formation). Preclinical investigation of a number of these compounds in different tumour models is currently underway.
Virulizin®, a sterile liquid drug formulation for injection, is also being developed. Virulizin® is a new drug with novel biological response modifier activities. It has been shown to stimulate normal peripheral blood monocytes to express cytocidal activity in a dose-dependent manner. North American clinical investigations have focused on advanced pancreatic cancer, malignant melanoma, invasive cervicaluterine carcinoma and HIV-related Kaposi's sarcoma.
Lorus Therapeutics' objective is to maximize the therapeutic value and potential commercial success of its technology. The Company intends to pursue specific developmental, manufacturing, marketing and distribution arrangements with one or more strategic pharmaceutical partners. No such arrangements have been finalized, but the Company is in late-stage discussions with potential strategic partners.
To expand its product pipeline, Lorus Therapeutics is currently reviewing in-licensing opportunities involving new products and technologies in the areas of oncology. Lorus is focusing its efforts on developing therapies with different targets to provide tools for the management of the disease. By treating patients using drugs from several different therapeutic areas, using each drug alone or in combination, the chances of successfully managing cancer can be increased significantly. Lorus is currently developing cytostatic and immunotherapy drug candidates and will continue to look for products in different areas.
| Contact Details: |
| 2 Meridian Road |
| Toronto |
| Ontario |
| M9W 4Z7 |
| Canada |
| Tel: | 416-798-1200 |
| Fax: | 416-798-2200 |
| Email: | info@lorusthera.com |
| WWW: | www.lorusthera.com/
|
|
Loading...
|
Recent Publications by Lorus Therapeutics: |  |
Virulizin((R)) induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors.
Virulizin((R)) has demonstrated strong antitumor efficacy in a variety of... | 21st March, 2008
| Research and Development Department, Lorus Therapeutics Inc., 2 Meridian
| Cancer Immunol Immunother. 2008 Dec;57(12):1757-69. Epub 2008 Mar 20.
DOI Direct Link |
Global comparative analysis of ESTs from the southern cattle tick, Rhipicephalus (Boophilus) microplus.
BACKGROUND: The southern cattle tick, Rhipicephalus (Boophilus) microplus,... | 16th January, 2008
| Lorus Therapeutics Inc; 2 Meridian Road, Toronto, ON M9W 4Z7, Canada.
| BMC Genomics. 2007 Oct 12;8:368.
DOI Direct Link |
Virulizin, a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo.
Virulizin, a novel biological response modifier, has demonstrated broad... | 31st October, 2007
| Research and Development Department, Lorus Therapeutics Inc., 2 Meridian
| Int Immunopharmacol. 2007 Oct;7(10):1350-9. Epub 2007 Jun 26.
DOI Direct Link |
RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo.
RNA interference, a posttranscriptional gene-silencing mechanism, has... | 26th April, 2007
| Lorus Therapeutics Inc., Toronto, Ontario, Canada.
| Anticancer Drugs. 2007 Apr;18(4):377-88.
DOI Direct Link |
GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.
GTI-2501 is a 20-mer oligonucleotide that is complementary to a coding... | 3rd February, 2007
| Lorus Therapeutics
| Int J Oncol. 2006 Feb;28(2):469-78.
|
→View more Lorus Therapeutics research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 530 times since April 2007, the link to the organisation's website has been followed 73 times Recent Search Terms used to find this page: lorus therapautics | lorus therapeutic latest news | lorus therapautics | Virulizin R induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors | Lorus Therapeutics Inc Ontario Canada | Virulizin Lorus Therapeutic | lorus | lorus therapeutics | lorus pharmaceutical | lorus technologies rights | . Search for more companies in Toronto Search for more companies in Ontario This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Lorus Therapeutics |
